Be the first to review this item
Gliatilin (Cholini alfosceras, Choline alfoscerate) - central cholinomimetic action with a primary effect on the central nervous system. It has a neuroprotective effect. Choline release takes place in the brain; Choline is involved in the biosynthesis of acetylcholine (one of the main mediators of nerve excitation). Alfostserat biotransformed to glycerophosphate, which is a precursor of phospholipids.
Gliatilin improves the transmission of nerve impulses in the cholinergic neurons; positive effect on the plasticity and neuronal membrane receptor function. Increases cerebral blood flow, enhances metabolic processes and activates the brain structure of the reticular formation and restores consciousness in traumatic brain damage.
It has a preventive and a corrective effect on the factors of involution psychoorganic syndrome, such as changing the composition of phospholipid membranes of neurons and decreased cholinergic activity.
In experimental studies have shown that Gliatilin stimulates a dose-dependent release of acetylcholine in physiological conditions, the transmission of nerve impulses.
It increases acetylcholine synthesis and positively affects the transmission of nerve impulses, and glycerophosphate involved in the synthesis of phosphatidylcholine (phospholipid membrane) to improve the elasticity of the membrane and the function of receptors.
Drug Interactions drug Gliatilin not established.
In chronic cerebrovascular insufficiency, changes in emotional and behavioral sphere and multi-infarct dementia, inside - 400 mg (1 capsule) 3 times a day.
Duration of treatment - 3-6 months.
Effects on ability to drive vehicles and management mechanisms Gliatilin does not affect the patient's ability to engage in potentially hazardous activities.
Important notice- the outer box design may vary before prior notice!